Last: | $906.71 |
---|---|
Change Percent: | 1.28% |
Open: | $902.71 |
Close: | $906.71 |
High: | $912 |
Low: | $878.5 |
Volume: | 4,526,566 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$906.71 | $902.71 | $906.71 | $912 | $878.5 | 4,526,566 | 07-02-2024 |
$914.37 | $911.77 | $914.37 | $916.83 | $904.31 | 2,546,119 | 07-01-2024 |
$905.38 | $911.31 | $905.38 | $915.54 | $905.38 | 3,375,426 | 06-28-2024 |
$909.04 | $903.53 | $909.04 | $909.57 | $899.72 | 1,948,132 | 06-27-2024 |
$901.26 | $904 | $901.26 | $906.345 | $897.84 | 2,232,075 | 06-26-2024 |
$904.61 | $891.77 | $904.61 | $909.42 | $891.5 | 2,839,806 | 06-25-2024 |
$890.11 | $889.975 | $890.11 | $903.5786 | $882.94 | 2,878,199 | 06-24-2024 |
$883.88 | $885.66 | $883.88 | $891.97 | $879.8 | 3,448,680 | 06-21-2024 |
$885.99 | $893 | $885.99 | $905.45 | $870.13 | 3,359,987 | 06-20-2024 |
$891.46 | $887 | $891.46 | $894.87 | $884 | 2,437,038 | 06-19-2024 |
$891.46 | $887 | $891.46 | $894.87 | $884 | 2,437,038 | 06-18-2024 |
$885.01 | $878 | $885.01 | $892.2 | $876.86 | 2,532,240 | 06-17-2024 |
$878.45 | $882.33 | $878.45 | $884.61 | $876 | 2,023,264 | 06-14-2024 |
$883.33 | $869.025 | $883.33 | $885.06 | $861.5 | 2,243,419 | 06-13-2024 |
$867.3 | $872 | $867.3 | $872 | $853.85 | 2,594,601 | 06-12-2024 |
$865.82 | $882.14 | $865.82 | $882.14 | $852.23 | 4,109,073 | 06-11-2024 |
$865 | $853.98 | $865 | $871.63 | $849.39 | 3,444,498 | 06-10-2024 |
$849.99 | $837.76 | $849.99 | $856.81 | $837.01 | 2,468,834 | 06-07-2024 |
$837.29 | $834.88 | $837.29 | $846.9742 | $831.88 | 2,108,975 | 06-06-2024 |
$831.76 | $830.49 | $831.76 | $838.45 | $817.62 | 2,169,003 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 16:00:05 ET Terence Flynn from Morgan Stanley issued a price target of $1,023.00 for LLY on 2024-07-02 14:30:00. The adjusted price target was set to $1,023.00. At the time of the announcement, LLY was trading at $906.1521. The overall price target consensus i...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participan...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...